The new coronavirus, called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), was discovered in late December 2019 after cases were reported in the city of Wuhan, China. In January 2020, the World Health Organization (WHO) officially declared the Coronavirus Disease 2019 (COVID-19) as a pandemic, which has an official record of around 500 million cases and more than 6.0 million deaths in worldwide. An important factor in controlling the pandemic is the development of more effective and efficient diagnostic tests. In this context, this review has as its main proposal to discuss the effective differences between the possible diagnostic tests, the implications of molecular and serological methods available on the market and the analytical and clinical parameters involved in the development and application of these methods.

In December 2019, the World Health Organization officially announced the discovery and fast spread of the new coronavirus disease (COVID-19), which is caused by the SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), discovered in Wuhan, China. Since the beginning of the pandemic, there has been a global search for the discovery of antiviral candidates capable of treating the infection caused by SARS-CoV-2. However, none of them has shown proved efficacy and low toxicity for an effective dose. In view of this, research with plants based in natural products has been highlighted by the low toxicity of its metabolites and reduced side effects, since plants have been used for millennia in the treatment of various diseases. In this review, we highlight some plant species and plant metabolites belonging to the structural class of phenolic, alkaloids and terpenes with promising antiviral potential against coronavirus that could be explored as potential candidates for drug prototypes in the treatment of COVID-19.

Abstract This work describes a pharmacological screening of Brazilian medicinal plants through their anti-inflammatory and cytotoxicity activities. Cytotoxicity activity of Mouriri elliptica and Alchornea glandulosa as well as the drugs celecoxib and doxorubicin were evaluated in cultures of peritoneal macrophages. The immune system influence of these samples was analyzed by determining production/inhibition of NO, production of tumor necrosis factor-α and production of interleukin-10. Regarding the production/inhibition of NO, there was NO production by M. elliptica and NO inhibition when the cells were exposed to A. glandulosa; Macrophages generally produce more NO, plus TNF-α and less IL-10, when associated to the tumor phenomenon, characterizing the inflammation involved in cancer. A. glandulosa showed anti-inflammatory effect, inhibited NO production and it was associated with low TNF-α production, although not as low as the macrophages associated with celecoxib and doxorubicin. These cytokines were not different in animals with tumor. Celecoxib confirms its anti-inflammatory action by markedly inhibiting NO and TNF-α, but also inhibiting IL-10 which is an anti-inflammatory cytokine. Doxorubicin inhibited NO in a higher percentage in the group of animals with tumor, although the literature reports that this drug stimulates the production of NO and this collaborates with its cytotoxic effect.

This work aims to develop a rapid and reliable method by HPLC-QqQ-MS/MS for identification and quantification of Kaurenoic acid (KA) in extract, tincture and syrup from Mikania glomerata. The developed method allows identifying and quantifying KA in complex samples obtained from extract marketed in pharmaceutical industry, a tincture prepared with the leaves from plant and two syrups purchased in the local market. The quantification was performed using standard addition calibration curve. An accurate method for Kaurenoic acid determination in M. glomerata samples was developed. The concentrations of KA found in M. glomerata were 0.19 mg mL-1 in the commercial extract, 0.93 mg mL-1 in the tincture, 3.00 x 10-3 mg mL-1 in the syrup B and in syrup A was not possible to quantify due to the concentration is below the detection limit. Since most reports describe the quantification of the main active constituent (coumarin) and do not provide relevant information on the quantification of KA in these sample types (syrup and tincture), the developed method represents an excellent alternative for agile and efficient analysis of the KA in complex matrices from simple dilution.

ABSTRACT Candida spp. is associated with almost 80% of all nosocomial fungal infections and is considered a major cause of blood stream infections. In humans, Cryptococcosis is a disease of the lungs caused by the fungi Cryptococcus gattii and Cryptococcus neoformans. It can be potentially fatal, especially in immune-compromised patients. In a search for antifungal drugs, Deguelia duckeana extracts were assayed against these two fungi and also against Candida albicans, which causes candidiasis. Hexane branches and CH2Cl2 root extracts as well as the substances 4-hydroxylonchocarpine, 3,5,4′-trimethoxy-4-prenylstilbene and 3′,4′-methylenedioxy-7-methoxyflavone were assayed to determine the minimal inhibitory concentration. Phytochemical study of CH2Cl2 root and hexane branch extracts from D. duckeana A.M.G. Azevedo, Fabaceae, resulted in the isolation and characterization of nine phenolic compounds: 4-hydroxyderricine, 4-hydroxylonchocarpine, 3′,4′,7-trimethoxy-flavonol, 5,4′-dihydroxy-isolonchocarpine, 4-hydroxyderricidine, derricidine, 3,5,4′-trimethoxy-stilbene, 3′,4′,7-trimethoxyflavone and yangambin. The only active extract was a CH2Cl2 root showing minimal inhibitory concentration 800 µg/ml against C. gattii, and the investigation of compounds obtained from this extract showed that 4-hydroxylonchocarpine was active against all three fungi (C. neoformans, C. gattii and C. albicans). These results suggest that D. duckeana extracts have potential therapeutic value for the treatment of pathogenic fungi.